Sareum Holdings PLC
("Sareum" or the "Company")
New Patent Allowance
Cambridge, UK, 15 March 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today announces that the European Patent Office has issued a Notice of Allowance for a patent relating to SDC?1801, the Company's lead TYK2/JAK1 kinase inhibitor, currently in clinical development in Australia.
The newly approved European patent application, EP3864009, safeguards SDC?1801, its medical applications particularly in the treatment of autoimmune diseases, and certain methods of synthesis.
This follows approvals in 2023 by the China National Intellectual Property Administration, and the Japan Patent Office for the same protections.
Patent applications in the US (US2021387981) and other territories are still under review.
The Company expects that the patent will be granted in the near future, subject to certain formalities being completed.
Dr John Reader, Sareum's Chief Scientific Officer, commented: "This new patent allows us to enhance our intellectual property portfolio in a crucial market. Our Phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the Single Ascending Dose (SAD) and Food Effect study revealing no significant adverse events. This progress highlights the potential of SDC-1801 to achieve therapeutic drug levels in the bloodstream through once-daily oral dosing."
- Ends -
For further information, please contact:
| Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations
|
01223 497700 ir@sareum.co.uk
|
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
| Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
| Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
| ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Kumail Waljee |
0203 709 5700 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019 ("UK MAR").
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.